Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”

Detalles Bibliográficos
Autores principales: Nasser, Azmi, Hull, Joseph T., Liranso, Tesfaye, Fry, Nicholas, Cutler, Andrew J., Rubin, Jonathan, Childress, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712289/
https://www.ncbi.nlm.nih.gov/pubmed/36331781
http://dx.doi.org/10.1007/s40263-022-00967-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712289/
https://www.ncbi.nlm.nih.gov/pubmed/36331781
http://dx.doi.org/10.1007/s40263-022-00967-5

Ejemplares similares